CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for StemLife Berhad is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

StemLife Berhad
B-7-15
Megan Avenue II, 12 Jalan Yap Kwan Seng
Phone: +60 321638800p:+60 321638800 KUALA LUMPUR, 50450  Malaysia Fax: +60 321649808f:+60 321649808
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
StemLife Berhad is a cell-banking company. The Company's principal activities are investment holding and the provision of collection, testing, processing and preservation of umbilical cord blood stem cells (UCBSC), umbilical cord tissues (UCT), Wharton Jelly (WJ) and peripheral blood stem cells (PBSC) services. The Company's other activities include stem cell therapy and consultancy services. It operates through two segments: Provision of collection, testing, processing and preservation of UCBSC, UCT, WJ and PBSC, and Corporate, which includes investment in properties. It offers an option to collect and store the cord lining, which is a sheet-like membrane that protects the umbilical vein, arteries and Wharton's Jelly. The Company also offers the CelOptima cord lining technology. The Company offers MyGenes, which provides genetic screening. It enables saving of three types of stem cells, including hematopoietic stem cells, mesenchymal stem cells and epithelial stem cells.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20166/30/2016Yes----

Industries
SIC Code Description
8099 Health and allied services, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Independent Non-Executive Chairman of the Board Choon HouHo 43 12/11/2013 12/9/2013
Chief Executive Officer, Executive Director SophianBin Abdul Rahman 41 11/11/2015 7/1/2015
Acting Chief Financial Officer Yee FongHoo 43 7/1/2015 7/1/2015
12 additional Officers and Directors records available in full report.

Business Names
Business Name
STEMLFE
StemLife Berhad

General Information
Outstanding Shares: 247,500,000 (As of 12/31/2016)
Shareholders: 1,859
Stock Exchange: KUL
Fax Number: +60 321649808


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023